Skip to main content

Generics

  • Watson files for approval of generic painkiller

    PARSIPPANY, N.J. — Watson Pharmaceuticals is looking to become the first to market a generic version of a painkiller made by Pfizer, the drug maker said Friday.

    Watson said it filed a regulatory approval application with the Food and Drug Administration for morphine sulfate and naltrexone hydrochloride extended-release capsules in the 30-mg/1.2-mg, 50-mg/2-mg, 60-mg/2.4-mg, 80-mg/3.2-mg and 100-mg/4-mg strengths. The drug is a generic version of Embeda, made by Pfizer subsidiary King Pharmaceuticals.

  • Study: People with optimal levels of vitamin D have lower diabetes incidence

    NEUHERBERG, Germany — Scientists at the Helmholtz Zentrum München have shown that people with good vitamin D status have a lower risk of developing Type 2 diabetes, according to a study released Sept. 30.

  • Study: Too much TV may be an indicator of poor blood-glucose control

    ALEXANDRIA, Va. — Type 1 diabetics who watch the most television have poorer blood-sugar control on average, according to a study published online Sept. 16 by the American Diabetes Association's journal Diabetes Care.

    In the cross-sectional study, self-report questionnaires were used to assess media consumption habits, physical activity and socioeconomic status in 296 children, adolescents and young adults with Type 1 diabetes.

  • Perrigo receives tentative FDA approval for generic scalp dermatosis drug

    ALLEGAN, Mich. — The Food and Drug Administration has granted tentative approval to a drug made by Perrigo for dermatosis of the scalp.

    Perrigo's clobetasol propionate emulsion foam in the 0.05% strength is a generic version of Stiefel Labs' Olux-E Foam. Sales for the branded version of the drug were $40 million during the 12-month period ended in September, according to Wolters Kluwer.

  • Branded-to-generic shift impacts Fred's September comps

    MEMPHIS, Tenn. — Fred’s posted a 1% gain in sales, to $17.5 million, for the five weeks ended Oct. 1.

    Comparable store sales for September increased 1.1%; comparable store sales were flat in the year-earlier month. The September total sales comparison was adversely affected by store-closing sales that occurred last year during the month.

  • Harris Teeter to host grand reopening featuring flu shots, health screenings

    CHARLOTTE, N.C. — Harris Teeter on Oct. 8 and 9 will host a grand reopening celebration featuring a free sampling event at its Norfolk, Va., Harris Teeter, the grocer announced Thursday.

    As part of the events, Harris Teeter will host a flu shot clinic at the pharmacy throughout the weekend. Free health screenings also will be conducted from 11 a.m. through 4 p.m. Shoppers can receive blood-glucose testing, biometric measurement and a health risk assessment.

  • AccuDial expands packaging portfolio with Stephen Key acquisition

    PALM BEACH GARDENS, Fla. — AccuDial Pharmaceutical on Tuesday acquired Stephen Key Design in a move that will expand AccuDial’s patent portfolio to more than 50 patents for weight-based dosing and other extended content rotating labels, which add 75% more labeling space to a container.

  • Amneal launches generic Felbatol

    BRIDGEWATER, N.J. — Amneal last month launched its version of an epilepsy treatment.

    The drug maker said that felbamate tablets are available in 400-mg and 600-mg strengths, following approval from the Food and Drug Administration last month. The drug is the first-to-market generic equivalent of Meda Pharmaceuticals' Felbatol, Amneal said.

    The Amneal generic is available in 90-count bottles in 400-mg strength and 90- and 180-count sizes in 600-mg strength, the company said.

    Annual U.S. sales of Felbatol totaled $43.7 million, according to IMS Health data.

X
This ad will auto-close in 10 seconds